alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit








EXECUTIVE DEPARTURE AGREEMENT


Integer Holdings Corporation (the “Company”) and Thomas J. Hook (“Executive”) enter into this Executive Departure Agreement (this “Agreement”) on March 25, 2017. This Agreement refers to, and, to the extent necessary to carry out the provisions of this Agreement, supersedes, the provisions of the Employment Agreement, dated August 5, 2016, between the Company and Executive (the “Employment Agreement”). Section references contained herein are references to sections of the Employment Agreement.


In consideration of the covenants and agreements contained in this Agreement, the Company and Executive agree as follows: 


		
	1.
	As of the date hereof, Executive ceases to be the President and Chief Executive Officer of the Company and shall resign from all positions he holds with the Company and its subsidiaries.  Effective as of the date of the Company’s 2017 Annual Meeting of Stockholders (the “Meeting Date”), Executive will cease to be employed by the Company and will cease to serve as a Director of the Company.


		
	2.
	The Company will provide Executive with (i) the compensation set forth in Section 3.1, the other benefits set forth in Section 3.3 and expense reimbursement in accordance with Section 4 through the Meeting Date, and (ii) the payments and benefits on the basis of a termination of employment occurring on the Meeting Date pursuant to Section 6.2 of the Employment Agreement. The foregoing fully satisfies any obligations the Company may have to Executive under the Employment Agreement or otherwise in connection with the removal of Executive from the offices of President and Chief Executive Officer and with the termination of Executive’s employment.


		
	3.
	The Company and Executive agree that Section 8.1 and Section 8.2 of the Employment Agreement shall apply to Executive. 




Agreed and Acknowledged:


Integer Holdings Corporation




____/s/ Bill R. Sanford________        __/s/ Thomas J. Hook_______
By: Bill R. Sanford        Thomas J. Hook
Its: Chairman
# C_2015354EN.01003401.xml

| 26.10.2015 | EN | Official Journal of the European Union | C 354/34 |
| --- | --- | --- | --- |

26.10.2015

EN

Official Journal of the European Union

C 354/34

---

Judgment of the General Court of 10 September 2015 — Laverana v OHIM (BIO FLUIDE DE PLANTE PROPRE FABRICATION)

(Case T-568/14) (1)

1

((Community trade mark - Application for Community figurative mark BIO FLUIDE DE PLANTE PROPRE FABRICATION - Absolute ground for refusal - Descriptive character - Article 7(1)(c) of Regulation (EC) No 207/2009))

(2015/C 354/39)

Language of the case: German

Parties

Parties

Applicant: Laverana GmbH & Co. KG (Wennigsen, Germany) (represented by: J. Wachinger, M. Zöbisch and D. Chatterjee, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: A. Schifko, acting as Agent)

Defendant:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of OHIM of 27 May 2014 (Case R 120/2014-4) concerning an application for registration of the figurative sign BIO FLUIDE DE PLANTE PROPRE FABRICATION as a Community trade mark.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Laverana GmbH & Co. KG to bear the costs. |
| --- | --- |

2.

Orders Laverana GmbH & Co. KG to bear the costs.

---

(1)  OJ C 361, 13.10.2014.

1

---
#### § 522.2340 Sulfomyxin.

(a) *Specifications.* Sulfomyxin for injection is sterile. It is derived from the antibiotic substance produced by the growth of *Bacillus polymyxa* or is the same substance produced by any other means.

(b) *Sponsor.* See No. 054771 in [§ 510.600(c) of this chapter](/on/2024-09-17/title-21/section-510.600#p-510.600(c)).

(c) *Special considerations.* The quantities of antibiotic in [paragraph (e)](/on/2024-09-17/title-21/section-522.2340#p-522.2340(e)) of this section refer to the activity of the appropriate standard.

(d) *Related tolerances.* See [§ 556.700 of this chapter](/on/2024-09-17/title-21/section-556.700).

(e) *Conditions of use.*

(1) It is used or intended for use in chickens and turkeys as an aid in the treatment of disease caused or complicated by *E. coli,* such as colibacillosis and complicated chronic respiratory disease.

(2) It is administered by subcutaneous injection as follows:

| Age of birds in days | Antibiotic activity | |
| --- | --- | --- |
| Chickens (units) | Turkeys (units) |
| 1 to 14 | 12,500 | 12,500 |
| 15 to 28 | 25,000 | 25,000 |
| 29 to 63 | 50,000 | 50,000 |
| Over 63 | 50,000 | 100,000 |

(3) A second injection may be given 3 days later if symptoms persist.

(4) Not for use in laying hens; do not treat chickens within 5 days of slaughter. Do not treat turkeys within 7 days of slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[[40 FR 13858](https://www.federalregister.gov/citation/40-FR-13858), Mar. 27, 1975, as amended at [79 FR 16196](https://www.federalregister.gov/citation/79-FR-16196), Mar. 25, 2014; [88 FR 14900](https://www.federalregister.gov/citation/88-FR-14900), Mar. 10, 2023]
#### POWER *v.*BALITZ.

Certiorari to Benzie; Lamb, J.

Submitted June 27, 1914.

(Calendar No. 26,289.)

Decided June 14, 1915.

Mandamus by Delbert Power against Fred Balitz, treasurer of the township of Platte, Benzie county, to require respondent to pay an order. From an order denying relief relator brings certiorari.

Affirmed.

*Gleason & Lee (Myron H. Walker,*of counsel), for relator.

*Warner, Raudabaugh & Person,*for respondent.

Bird, J.

Substantially the same state of facts and the same legal questions are involved in this case as were considered and passed upon by this court in *Power*v. *Gray, ante,*646 (153 N. W. 37), filed herewith. This case is ruled by that .one, and the order made herein by the trial court will be affirmed, with costs to the respondent.

Brooke, C. J., and McAlvay, Kuhn, Stone, Ostrander, Moore, and Steere, JJ., concurred.
I OFFICE OF THE ATTORNEY GENERAL OF TEXAS 

I’ AUSTIN 

fleoaable WI A. Davis 

Stat0 &*gbtr*r 

Stat4 Board of 3Ualth Awtln, 2um 

bar slra 
iionQrable ii. A. rnVL8, pEgI2 2 
^ 

C 

Lionarab k’. A. Davis, paec 3 

is.aAy, v1tb the rdopU0n doares at th4 Court ma 

sadh~alad~aluigemeyba opened on.Q uponorder OS 

a .Courb of ~30~4.. Upon reolotpt of BQW of eanulnient of crdapfioa;*o6ld R4 

$ 

Lstrar oi Vftal btatlrticr 

-31 rc8tors tha origina napw al tha ah&Ad rpd ?.he 

Aolwl QP hi.8 neturol prrent8 or pzwlt to t&a 

rcacmi of birth OS euch ahild. Pravldwl furSher 

that e4optIon rarba uacler sr28tlng 18u pior to tize 

p8r98g4 of W8 Aot, wey be Ngf8t4F44 *it& the 

Bwoau OS VAtal Statiotlos upera svor~ appli68tm4 

of sither adaptlvo parent or guardlea of the aQepW3 

ouM, shou th4 Aam on4 eddr-48894 OS the aatula 

parantai ff knmm, or of the ahibId' next k&n, She 

Qate of bLrth aa4 the noptQ OS ruab ahiLd before ud 

a ttal t%qtimr, r the nma8 an4 ad4romses of foeter 

goats, to@hdmX’ Wi+& proof Of adopt;lC#, either bT 

cartLI;ed copy c# the reatml of the aStidwit OS 

aQoptiori, or the Court or&r OS auoptlon.’ 

'phfo 58 the only prevtsror~ ot our Mv permlttlag a 

roglstretton suah 810 the on@ aolrt@apUtsd by the oertlfiaats 

eubaltte4. TtaWwly cont45plaScr a legal 44aptio~, anblays 

doVn apeaitio awquirswsnt;s whzoh Pwt be fulSil&d prior to the 

regZetration. '&a certifti64t,o rubritted doe8 not SuUiU thaw 

r4wlrom6rst8, It L8 not a aertifisd oupy of an osiw of sdoptiOA, &OF 18 it 0 SVOl-A 8ppli6asiOA at 4~thrr adO<~VO m4At 

or guar<llm OS ths 846pteQ saJild, 8hoViag "?&w zuk@M aad addre8w8 QS the mtural parsxitofs, if Imaun, ar of the awl4@8 

~clxt k3.q the date of bLrtb aad tha nbm of rush ahIld BISore 

and after adoption, the wunao and Oddro88os OX Somter pawnts, 

together With proof oi adoptlea." 

Xt 1s tbercrfars ow opinion that t&4 birth aert%ffoote suba+tted should Aot be noospted by tha State Reg.IrtHw 

En lieu of the osrtlfled aopy of e4aptioo Qooree provtded for 

bg 6aiQ pknagrqih 26 of Rule &7a, ktlalo 4477, V. R. C. f). 

ln vlcw of our anuwur to your Sir& gwrtian, it becozeu unnecessary to answer ths second. 
159
# C_2016402EN.01003902.xml

| 31.10.2016 | EN | Official Journal of the European Union | C 402/39 |
| --- | --- | --- | --- |

31.10.2016

EN

Official Journal of the European Union

C 402/39

---

Judgment of the General Court of 15 September 2016 — Philip Morris v Commission

(Case T-800/14) (1)

1

((Access to documents - Regulation (EC) No 1049/2001 - Documents drawn up in the context of the preparatory works leading to the adoption of the directive on the approximation of the laws, regulations and administrative provisions of the Member States concerning the manufacture, presentation and sale of tobacco and related products - Refusal to grant access - Exception relating to the protection of legal advice - Exception relating to the protection of the decision-making process - Rights of the defence - Overriding public interest))

(2016/C 402/44)

Language of the case: English

Parties

Parties

Applicant: Philip Morris Ltd (Richmond, United Kingdom) (represented by: K. Nordlander and M. Abenhaïm, lawyers)

Applicant:

Defendant: European Commission (represented by: J. Baquero Cruz and F. Clotuche-Duvieusart, acting as Agents)

Defendant:

Re:

Re:

Application based on Article 263 TFEU and seeking annulment of Commission Decision Ares(2014) 3388066 of 29 September 2014, in so far as it refuses to grant the applicant full access to the requested documents, with the exception of the redacted personal data contained therein.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Philip Morris Ltd to pay the costs. |
| --- | --- |

2.

Orders Philip Morris Ltd to pay the costs.

---

(1)  OJ C 56, 16.2.2015.

1

---
# C_2016305EN.01002902.xml

| 22.8.2016 | EN | Official Journal of the European Union | C 305/29 |
| --- | --- | --- | --- |

22.8.2016

EN

Official Journal of the European Union

C 305/29

---

Judgment of the General Court of 14 July 2016 — Latvia v Commission

(Case T-661/14) (1)

1

((EAGGF, EAGF and EAFRD - Expenditure excluded from financing - Flat-rate financial correction - Conditionality - Minimum requirements for good agricultural and environmental conditions - Norms - Article 5(1) and Annex IV to Regulation (EC) No 1782/2003 - Article 6(1) and Annex III to Regulation (EC) No 73/2009))

(2016/C 305/40)

Language of the case: Latvian

Parties

Parties

Applicant: Republic of Latvia (represented by: I. Kalniņš and D. Pelše, acting as Agents)

Applicant:

Defendant: European Commission (represented by: A. Sauka and D. Triantafyllou, acting as Agents)

Defendant:

Re:

Re:

Application based on Article 263 TFEU and seeking annulment of Commission Implementing Decision 2014/458/EU of 9 July 2014 on excluding from European Union financing certain expenditure incurred by the Member States under the Guarantee Section of the European Agricultural Guidance and Guarantee Fund (EAGGF), under the European Agricultural Guarantee Fund (EAGF) and under the European Agricultural Fund for Rural Development (EAFRD) (OJ 2014 L 205, p. 62), in so far as that decision excludes from EU financing certain expenditure of the Republic of Latvia, amounting to EUR 739 393,95, due to the fact that it is incompatible with EU rules.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Annuls Commission Implementing Decision 2014/458/EU of 9 July 2014 on excluding from European Union financing certain expenditure incurred by the Member States under the Guarantee Section of the European Agricultural Guidance and Guarantee Fund (EAGGF), under the European Agricultural Guarantee Fund (EAGF) and under the European Agricultural Fund for Rural Development (EAFRD), in so far as that decision excludes from EU financing certain expenditure of the Republic of Latvia, amounting to EUR 739 393,95, due to the fact that it is incompatible with EU rules; |
| --- | --- |

1.

Annuls Commission Implementing Decision 2014/458/EU of 9 July 2014 on excluding from European Union financing certain expenditure incurred by the Member States under the Guarantee Section of the European Agricultural Guidance and Guarantee Fund (EAGGF), under the European Agricultural Guarantee Fund (EAGF) and under the European Agricultural Fund for Rural Development (EAFRD), in so far as that decision excludes from EU financing certain expenditure of the Republic of Latvia, amounting to EUR 739 393,95, due to the fact that it is incompatible with EU rules;

| 2. | Orders the European Commission to pay the costs. |
| --- | --- |

2.

Orders the European Commission to pay the costs.

---

(1)  OJ C 395, 10.11.2014.

1

---
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.4120 Bone cutting instrument and accessories. ( a ) *Identification.* A bone cutting instrument and accessories is a metal device intended for use in reconstructive oral surgery to drill or cut into the upper or lower jaw and may be used to prepare bone to insert a wire, pin, or screw. The device includes the manual bone drill and wire driver, powered bone drill, rotary bone cutting handpiece, and AC-powered bone saw.
( b ) *Classification.* Class II.
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.5200 External cardiac compressor. ( a ) *Identification.* An external cardiac compressor is an externally applied prescription device that is electrically, pneumatically, or manually powered and is used to compress the chest periodically in the region of the heart to provide blood flow during cardiac arrest. External cardiac compressor devices are used as an adjunct to manual cardiopulmonary resuscitation (CPR) when effective manual CPR is not possible (*e.g.,* during patient transport or extended CPR when fatigue may prohibit the delivery of effective/consistent compressions to the victim, or when insufficient EMS personnel are available to provide effective CPR).
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Nonclinical performance testing under simulated physiological conditions must demonstrate the reliability of the delivery of specific compression depth and rate over the intended duration of use.
( 2 ) Labeling must include the following: ( i ) The clinical training necessary for the safe use of this device;
( ii ) Adjunctive use only indication prominently displayed on labels physically placed on the device and in any device manuals or other labeling;
( iii ) Information on the patient population for which the device has been demonstrated to be effective (including patient size and/or age limitations, *e.g.,* adult, pediatric and/or infant); and
( iv ) Information on the time necessary to deploy the device as demonstrated in the performance testing.
( 3 ) For devices that incorporate electrical components, appropriate analysis and testing must demonstrate that the device is electrically safe and electromagnetically compatible in its intended use environment.
( 4 ) Human factors testing and analysis must validate that the device design and labeling are sufficient for effective use by the intended user, including an evaluation for the time necessary to deploy the device.
( 5 ) For devices containing software, software verification, validation, and hazard analysis must be performed.
( 6 ) Components of the device that come into human contact must be demonstrated to be biocompatible.
[81 FR 33133, May 25, 2016]
§ 74.2708 D&C Yellow No. 8. ( a ) *Identity and specifications.* The color additive D&C Yellow No. 8 shall conform in identity and specifications to the requirements of § 74.1708(a)(1) and (b).
( b ) *Uses and restrictions.* D&C Yellow No. 8 may be safely used for coloring externally applied cosmetics in amounts consistent with good manufacturing practice.
( c ) *Labeling.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of D&C Yellow No. 8 shall be certified in accordance with regulations in part 80 of this chapter.
# C_2015198EN.01003702.xml

| 15.6.2015 | EN | Official Journal of the European Union | C 198/37 |
| --- | --- | --- | --- |

15.6.2015

EN

Official Journal of the European Union

C 198/37

---

Judgment of the General Court of 30 April 2015 — Tecalan v OHIM — Ensinger (TECALAN)

(Case T-100/14) (1)

1

((Community trade mark - Opposition proceedings - Application for Community word mark TECALAN - Earlier Community word mark TECADUR - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009))

(2015/C 198/50)

Language of the case: German

Parties

Parties

Applicant: Tecalan GmbH (Grünberg, Germany) (represented by: S. Holthaus, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: D. Walicka, acting as Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM, intervener before the General Court: Ensinger GmbH (Nufringen, Germany) (represented by: K. Gründig-Schnelle, lawyer)

Other party to the proceedings before the Board of Appeal of OHIM, intervener before the General Court:

Re:

Re:

Action brought against the decision of the First Board of Appeal of OHIM of 11 December 2013 (Case R 2308/2012-1), relating to opposition proceedings between Ensinger GmbH and Tecalan GmbH.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Tecalan GmbH to pay the costs. |
| --- | --- |

2.

Orders Tecalan GmbH to pay the costs.

---

(1)  OJ C 112, 14.4.2014.

1

---
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.9245 Automated blood cell separator. ( a ) *Identification.* An automated blood cell separator is a device that uses a centrifugal or filtration separation principle to automatically withdraw whole blood from a donor, separate the whole blood into blood components, collect one or more of the blood components, and return to the donor the remainder of the whole blood and blood components. The automated blood cell separator device is intended for routine collection of blood and blood components for transfusion or further manufacturing use.
( b ) *Classification.* Class II (special controls). The special control for this device is a guidance for industry and FDA staff entitled “Class II Special Controls Guidance Document: Automated Blood Cell Separator Device Operating by Centrifugal or Filtration Separation Principle.”
[72 FR 67644, Nov. 30, 2007]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5210 Ceruloplasmin immunological test system. ( a ) *Identification.* A ceruloplasmin immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the ceruloplasmin (copper-transporting serum protein) in serum, other body fluids, or tissues. Measurements of ceruloplasmin aid in the diagnosis of copper metabolism disorders.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 84 FR 71800, Dec. 30, 2019]
QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.5  


 
 

2003 INCENTIVE PLAN    
  


        For the 2003 fiscal year, a corporate executive will be awarded 100% of his or her target bonus amount (target amounts established in January by the Compensation
Committee) if the Company's [***] reaches its established budget for the year ([***]). An employee's actual bonus may vary above and below his or her
target according to the schedule below: 



	[***]	 	Bonus Amount
	

Below [***]	
 	

No bonus amount
	

[***] to [***]	
 	

50% - 100% of target on a pro rata basis
	

[***] to [***]	
 	

100% - 150% of target on a pro rata basis
	

[***] to [***]	
 	

150% - 175% of target on a pro rata basis






Adjustments
to the [***] targets shown above will be made for acquisitions made during the year in amounts agreed upon by the Compensation Committee and Executive Management of
the Company. Adjustments to the [***] targets shown above will be made for capital expenditures that exceed the capital expenditure budget for fiscal 2003 for amounts agreed
upon by the Compensation Committee and Executive Management. Actual [***] for the year used for incentive plan calculations will exclude [***] such as
[***]. 


CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.









QuickLinks


2003 INCENTIVE PLAN
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.1880 Pulmonary-function data calculator. ( a ) *Identification.* A pulmonary-function data calculator is a device used to calculate pulmonary-function values based on actual physical data obtained during pulmonary-function testing.
( b ) *Classification.* Class II (performance standards).
RULE 2:5 - Cancellation of Applic~tions. 

a. An Authority to Construct shall expire and the application 

shall be canceled t'tso (2) years· from the date of issuance of the 

Authority to Construct. 

b. An application for Permit to Operate existing equipment shall 

be cancel<!d tvto (2) years from the ·date of filing of the application. 
the size and location of the sampling platform; the access to the 

sampling platfonn; and the utilities for operating the sarrpling 

and testing equipment. The platform and access shali be constructed in accordance with the Eneral Industry Safety Order of 

the State of California. 

c. In acting upon a Permit to Operate, if the Ai1· Pollution 

Control Officer finds that the articles, machine, equipment or 

other contrivance has been constructed not in accordance with the 

Authority to Construct, he shall deny the Permit to Operate. The 

Air Pollution Control Officer shall.not accept any further application for Permit to Operate the ~rticle, machine, equipm~nt or 

other contrivance so con~tructed until he finds th~t the article, 

machine equipment or other constrivance has bc(n reconstructed in 

accordclnce with the Authot"i ty to Construct. 

d. The granting of a pennit does not exempt the holder from 

present and future regulations of the Air Pollution Control District.
## White Papers that Address the Subject of Compressor s, Pneumatic Devices, and Leaks

Attached are the comments of the Texas Pipeline Ass ociation to the white papers that address the subject of compressors, pneumatic devices and leaks . Please contact us at 512/478-2871 or via email at t exaspipelineassociation@yahoo.com if you have any questions or difficulties with the attachment. Thank you. 

### Pipeline Association <texaspipelineassociation@yaho o.com> Texas Mon 6/16/2014 5:52 PM To: OilandGas.Whitepapers <OilandGas.Whitepapers@epa.go v>;  1 attachment EPA White Paper Comments_0059.pdf; **Page 1**  **of 1**  **White Papers that Address the Subject of Compressor... -**  **OilandGas.Whitepapers**

**8/ 26/**  **2014 https://pod51045.outlook.com/owa/OilandGas.Whitepapers@epa.gov/**